Cargando…

The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials

BACKGROUND: Migraine is the most common primary headache among children and adolescents. The aim of this meta-analysis was to evaluate the efficacy and safety of antiepileptic drugs in the prevention of pediatric migraine. METHODS: PubMed, Cochrane Library, EMBASE and Chinese National Knowledge Infr...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Guoyong, Wang, Xingbang, Lv, Hongbo, Nonyane, Malebo Sarai Cheryl, Hou, Haiguang, Ma, Lin, Shan, Peiyan, Wu, Xinwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349954/
https://www.ncbi.nlm.nih.gov/pubmed/34430426
http://dx.doi.org/10.21037/tp-20-478
_version_ 1783735644578643968
author Jia, Guoyong
Wang, Xingbang
Lv, Hongbo
Nonyane, Malebo Sarai Cheryl
Hou, Haiguang
Ma, Lin
Shan, Peiyan
Wu, Xinwei
author_facet Jia, Guoyong
Wang, Xingbang
Lv, Hongbo
Nonyane, Malebo Sarai Cheryl
Hou, Haiguang
Ma, Lin
Shan, Peiyan
Wu, Xinwei
author_sort Jia, Guoyong
collection PubMed
description BACKGROUND: Migraine is the most common primary headache among children and adolescents. The aim of this meta-analysis was to evaluate the efficacy and safety of antiepileptic drugs in the prevention of pediatric migraine. METHODS: PubMed, Cochrane Library, EMBASE and Chinese National Knowledge Infrastructure (CNKI) databases were searched for eligible published RCTs from January 1970 to June 2020. Migraine frequency and ≥50% response rate were measured as the efficacy outcomes. We used “Risk of Bias” tool for quality assessment and RevMan5.3 software for statistical analysis. RESULTS: Four articles containing 7 RCTs with 794 participants compared the efficacy of AEDs with placebo. Four RCTs assessed topiramate vs. placebo and 3 RCTs evaluated divalproex sodium extended-release (DVPX ER) vs. placebo. The results demonstrated that children receiving antiepileptic drugs had a significant advantage in remitting the mean monthly migraine days compared to those who received placebo, with an MD of −0.48 (n=930, 95% CI: −0.84 to −0.12, Z=2.60, P=0.009). Topiramate significantly reduced monthly migraine days (MD =−0.70, n=489, 95% CI: −1.16 to −0.25, Z=3.01, P=0.003) but failed to improve the ≥50% response rate (MD =−1.50, n=489, 95% CI: 0.70 to 3.22, Z=1.05, P=0.30). DVPX ER did not significantly reduce monthly headache frequency (n=441, 95% CI: −0.70 to 0.47, Z=0.38, P=0.70) or improve the ≥50% response rate (n=441, 95% CI: 0.59 to 1.25, Z=0.82, P=0.41) compared with placebo. Topiramate and DVPX ER were related to higher rates of side effects and adverse reactions. DISCUSSION: Topiramate can reduce monthly headache days in children and adolescents with migraine. However, it failed to improve the ≥50% response rate. DVPX ER showed no difference from placebo in the prophylactic treatment pediatric migraine. Side effects seemed to be more frequent in topiramate and DVPX ER treated children but generally well-tolerated.
format Online
Article
Text
id pubmed-8349954
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-83499542021-08-23 The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials Jia, Guoyong Wang, Xingbang Lv, Hongbo Nonyane, Malebo Sarai Cheryl Hou, Haiguang Ma, Lin Shan, Peiyan Wu, Xinwei Transl Pediatr Original Article BACKGROUND: Migraine is the most common primary headache among children and adolescents. The aim of this meta-analysis was to evaluate the efficacy and safety of antiepileptic drugs in the prevention of pediatric migraine. METHODS: PubMed, Cochrane Library, EMBASE and Chinese National Knowledge Infrastructure (CNKI) databases were searched for eligible published RCTs from January 1970 to June 2020. Migraine frequency and ≥50% response rate were measured as the efficacy outcomes. We used “Risk of Bias” tool for quality assessment and RevMan5.3 software for statistical analysis. RESULTS: Four articles containing 7 RCTs with 794 participants compared the efficacy of AEDs with placebo. Four RCTs assessed topiramate vs. placebo and 3 RCTs evaluated divalproex sodium extended-release (DVPX ER) vs. placebo. The results demonstrated that children receiving antiepileptic drugs had a significant advantage in remitting the mean monthly migraine days compared to those who received placebo, with an MD of −0.48 (n=930, 95% CI: −0.84 to −0.12, Z=2.60, P=0.009). Topiramate significantly reduced monthly migraine days (MD =−0.70, n=489, 95% CI: −1.16 to −0.25, Z=3.01, P=0.003) but failed to improve the ≥50% response rate (MD =−1.50, n=489, 95% CI: 0.70 to 3.22, Z=1.05, P=0.30). DVPX ER did not significantly reduce monthly headache frequency (n=441, 95% CI: −0.70 to 0.47, Z=0.38, P=0.70) or improve the ≥50% response rate (n=441, 95% CI: 0.59 to 1.25, Z=0.82, P=0.41) compared with placebo. Topiramate and DVPX ER were related to higher rates of side effects and adverse reactions. DISCUSSION: Topiramate can reduce monthly headache days in children and adolescents with migraine. However, it failed to improve the ≥50% response rate. DVPX ER showed no difference from placebo in the prophylactic treatment pediatric migraine. Side effects seemed to be more frequent in topiramate and DVPX ER treated children but generally well-tolerated. AME Publishing Company 2021-07 /pmc/articles/PMC8349954/ /pubmed/34430426 http://dx.doi.org/10.21037/tp-20-478 Text en 2021 Translational Pediatrics. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Jia, Guoyong
Wang, Xingbang
Lv, Hongbo
Nonyane, Malebo Sarai Cheryl
Hou, Haiguang
Ma, Lin
Shan, Peiyan
Wu, Xinwei
The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials
title The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials
title_full The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials
title_fullStr The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials
title_full_unstemmed The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials
title_short The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials
title_sort efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349954/
https://www.ncbi.nlm.nih.gov/pubmed/34430426
http://dx.doi.org/10.21037/tp-20-478
work_keys_str_mv AT jiaguoyong theefficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials
AT wangxingbang theefficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials
AT lvhongbo theefficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials
AT nonyanemalebosaraicheryl theefficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials
AT houhaiguang theefficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials
AT malin theefficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials
AT shanpeiyan theefficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials
AT wuxinwei theefficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials
AT jiaguoyong efficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials
AT wangxingbang efficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials
AT lvhongbo efficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials
AT nonyanemalebosaraicheryl efficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials
AT houhaiguang efficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials
AT malin efficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials
AT shanpeiyan efficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials
AT wuxinwei efficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials